Neimeth International Pharmaceuticals plc announced earnings results for the year ended September 30, 2013. For the period, the company reported a turnover of NGN 2,017 billion as against NGN 1,519 billion (adjusted to 12 months) in 2012, showing a growth indices of 33%. With top line revenue of NGN 2,017 billion the company showed an impressive gross margin of NGN 642 million, a growth of 21% over 2012's NGN 529 million (adjusted to 12 months) Profit before tax showed a significant growth of 451%, NGN 183 million, against NGN 52 million in 2012.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 NGN | +3.90% | -2.44% | -17.53% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.53% | 4.6M | |
+45.82% | 765B | |
+40.95% | 632B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
+11.88% | 216B | |
-0.78% | 219B | |
+5.90% | 164B |
- Stock Market
- Equities
- NEIMETH Stock
- News Neimeth International Pharmaceuticals Plc
- Neimeth International Pharmaceuticals plc announces Earnings Results for the Year Ended September 30, 2013